Eli Lilly Reports New Phase 3b Data on Ixekizumab Plus Tirzepatide Combination

The signal here is biomarker breadth, not a clinical endpoint: a psoriasis antibody plus a GLP-1/GIP agent moving both inflammatory and metabolic markers suggests the two mechanisms interact rather than simply stack. That matters for Lilly's immunology and cardiometabolic franchises, where overlapping patient populations are already a commercial reality, and for rivals weighing similar combinations. The open question is whether exploratory biomarker separation converts into measurable skin or weight outcomes — and whether regulators and payers treat a combination as one product or two.